BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 6285061)

  • 21. Serum progesterone for the exclusion of early pregnancy in women at risk for recurrent gestational trophoblastic neoplasia.
    Rodriguez GC; Hughes CL; Soper JT; Berchuck A; Clarke-Pearson DL; Hammond CB
    Obstet Gynecol; 1994 Nov; 84(5):794-7. PubMed ID: 7936514
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Persistence of gestational trophoblastic disease for longer than 1 year following evacuation of hydatidiform mole.
    Elmer DB; Granai CO; Ball HG; Curry SL
    Obstet Gynecol; 1993 May; 81(5 ( Pt 2)):888-90. PubMed ID: 7682320
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low risk of relapse after achieving undetectable HCG levels in women with complete molar pregnancy.
    Wolfberg AJ; Feltmate C; Goldstein DP; Berkowitz RS; Lieberman E
    Obstet Gynecol; 2004 Sep; 104(3):551-4. PubMed ID: 15339768
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum 17 alpha-hydroxyprogesterone in patients with gestational trophoblastic neoplasms.
    Osathanondh R; Goldstein DP; Tulchinsky D; Finn AE
    Obstet Gynecol; 1977 Jan; 49(1):77-9. PubMed ID: 187990
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum interleukin-2 and soluble interleukin-2 receptor in gestational trophoblastic diseases.
    Shaarawy M; Darwish NA; Abdel-Aziz O
    J Soc Gynecol Investig; 1996; 3(1):39-46. PubMed ID: 8796806
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The complement fixing ability of putative circulating immune complexes in rheumatoid arthritis and its relationship to extra-articular disease.
    Bourke BE; Moss IK; Mumford P; Horsfall A; Maini RN
    Clin Exp Immunol; 1982 Jun; 48(3):726-32. PubMed ID: 6981475
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Circulating immune complexes detected by C1q solid phase assay in leprosy.
    Nuti M; D'Amelio R; Seminara R; Milano CF; Palmisano L; Aiuti F
    Int J Lepr Other Mycobact Dis; 1981 Mar; 49(1):27-30. PubMed ID: 6972924
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monitoring therapy in trophoblastic diseases by radioimmunoassay of pregnancy-specific beta 1-glycoprotein and the beta subunit of human chorionic gonadotropin.
    Than GN; Csaba IF; Bohn H; Szabó DG; Szalmásy M; Menczer G
    Oncodev Biol Med; 1982; 3(4):315-23. PubMed ID: 6291007
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum granulocyte macrophage colony stimulating factor (GM-CSF) in gestational trophoblastic diseases.
    Shaarawy M; el-Shobokshy AS; el-Noury AI
    Cytokine; 1995 Feb; 7(2):171-5. PubMed ID: 7540057
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low risk of relapse after achieving undetectable HCG levels in women with partial molar pregnancy.
    Wolfberg AJ; Growdon WB; Feltmate CM; Goldstein DP; Genest DR; Chinchilla ME; Berkowitz RS; Lieberman ES
    Obstet Gynecol; 2006 Aug; 108(2):393-6. PubMed ID: 16880311
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Persistent low-level "real" human chorionic gonadotropin: a clinical challenge and a therapeutic dilemma.
    Kohorn EI
    Gynecol Oncol; 2002 May; 85(2):315-20. PubMed ID: 11972394
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The immune system in disease: gestational trophoblastic tumours.
    Newlands ES; Fisher RA; Searle F
    Baillieres Clin Obstet Gynaecol; 1992 Sep; 6(3):519-39. PubMed ID: 1332835
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gestational trophoblastic neoplasia following molar ectopic pregnancy: a case report.
    Soares PD; Costa OL; Costa LA; Maestá I
    J Reprod Med; 2008 Aug; 53(8):579-82. PubMed ID: 18773621
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-dose methotrexate for gestational trophoblastic disease.
    Elit L; Covens A; Osborne R; Gerulath A; Murphy J; Rosen B; Sturgeon J
    Gynecol Oncol; 1994 Sep; 54(3):282-7. PubMed ID: 7522198
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum human chorionic gonadotropin regression pattern in persistent trophoblastic disease during chemotherapy.
    Lertkhachonsuk R; Limpongsanurak S
    J Med Assoc Thai; 2001 Jun; 84 Suppl 1():S352-9. PubMed ID: 11529357
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Guidelines following hydatidiform mole: a reappraisal.
    Kerkmeijer L; Wielsma S; Bekkers R; Pyman J; Tan J; Quinn M
    Aust N Z J Obstet Gynaecol; 2006 Apr; 46(2):112-8. PubMed ID: 16638032
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic characteristics of serum human chorionic gonadotropin titer regression following molar pregnancy.
    Schlaerth JB; Morrow CP; Kletzky OA; Nalick RH; D'Ablaing GA
    Obstet Gynecol; 1981 Oct; 58(4):478-82. PubMed ID: 7279342
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Combination chemotherapy with etoposide and cisplatin for high-risk, chemorefractory and recurrent gestational trophoblastic neoplasia].
    Jiang J; Nan FF; Yang XS; Zhang YZ; Wang B; Kong BH
    Zhonghua Fu Chan Ke Za Zhi; 2007 Sep; 42(9):595-9. PubMed ID: 17983513
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gestational trophoblastic disease.
    Soper JT
    Obstet Gynecol; 2006 Jul; 108(1):176-87. PubMed ID: 16816073
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictors of persistent disease in women with complete hydatidiform mole.
    Ayhan A; Tuncer ZS; Halilzade H; Küçükali T
    J Reprod Med; 1996 Aug; 41(8):591-4. PubMed ID: 8866387
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.